UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 29, 2014
REGENERX BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-15070 | 52-1253406 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
15245 Shady Grove Road, Suite 470 Rockville, MD |
20850 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (301) 208-9191
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure.
On September 3, 2014, the Company issued a press release announcing the receipt of $1 million representing the last tranche of a $2.5 million product license and securities purchase agreement with G-treeBNT Co., Ltd. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
Forward-Looking Statements
Any statements in this Form 8-K that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Forward-looking statements in this Form 8-K include, but are not limited to, statements regarding our strategic and research partnerships, future royalty and milestone payments, regulatory applications and approvals, the development of our drug candidates, the use of our drug candidates to treat various conditions, our growth strategy, and our financial needs. The proposed clinical trials and costs and resources to support such trials, as well as the other forward-looking statements, are expectations and estimates based upon information obtained and calculated by the Company at this time and are subject to change. Moreover, there is no guarantee any of these trials will be successful or confirm previous clinical results. Please view these and other risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the annual report on Form 10-K for the year ended December 31, 2013, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this Form 8-K represent the Company’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.
.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number |
Description | |
99.1 | Press Release dated September 3, 2014. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
REGENERX BIOPHARMACEUTICALS, INC. |
||||
By: | /s/ J.J. Finkelstein | |||
J.J. Finkelstein | ||||
President and Chief Executive Officer |
Date: September 3, 2014
EXHIBIT INDEX
Exhibit Number |
Description | |
99.1 | Press Release dated September 3, 2014. |
Exhibit 99.1
RegeneRx Receives $1 Million Pursuant
to Product License and
Stock Purchase Agreement
ROCKVILLE, Md. (September 3, 2014) – RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or “RegeneRx”) today announced that it received a payment of $1 million, representing the last tranche of a $2.5 million product license and securities purchase agreement with G-treeBNT Co., Ltd, to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S. G-treeBNT purchased 8,333,333 shares of common stock at $0.12 per share and retains an option until January 31, 2015 to purchase additional common stock for $825,000 at $0.15 per share. The licensing and securities purchase agreements have previously been filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2014.
Forward-Looking Statements
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements concerning the development and potential future commercialization of RGN-137 and RGN-259, and possible future milestone payments or exercise of G-treeBNT’s equity option. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. There can also be no assurance that any license agreement or product development program undertaken by RegeneRx or its licensees will be commercially successful. Please view these and other risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the annual report on Form 10-K for the year ended December 31, 2013, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.
# # #
For RegeneRx:
Lori Smith
301.208.9191
las@regenerx.com
F-/_N8D
M]_:"TT5G)$AV3G)J+)A>J&9A.[96Q__R@5FU(X&8$&,F'S/80:E5$^.S(7VE
M=TTX6H#%B?@U4B>W.KT3'IK$.I$B=+@#@2-U.3T5,+>3(.;F3$"+&
M'5YX4BM%$*"82=Y3AB4!<[HA(443 %?#U"(=:%K(Z(JU*)$.?!
M(X&@JJQ*I8YEJ]S:K=Z*./*R7?*"8?-4KDH9(8*`IH@@"%WP*R9T)-EBKO-T
M+)(3+O$R9/(ZK_1:K_8*+%KI&:L*KL!27]]:L`9[L`C[$:U9"@2;L`[[L+:J
M`A([L2J0KQ8++$^0L1H;4!S;L1[[L15$%B8VLB1;LB9K8HB6LHA&;BS;LB[[
MLC#KLHV#9;(*L3;_>[.\-K'EFK$@V[,!-18G2[(J.[1$&[-&FX^ED+1*N[1P
M5X.8^+10&[52NX\X6[56>[5Z)['<]`0@*[)!&[1$&[8I>[1DN[1)V[1HF[8S
M.[5L^[0U.U"E0W(#,J40\:'A@Y-S:WAXRW/L)R.\6*5)FA;)F#S'&$B\<1M[
MB+5,H;7RPK,_:P4H*[:2*[9D>[1F6PIJF[EMN[F.4Q2%%R`=!YT#$C!7@K>*
M9[I&JA"=1YY68T5[AYQ*R!;@.7F>$GD&DH:*BQB,&R]<*TE9,;*26[G"BVN7
MF[EJR[G(^[8O(4.#1:.6TEOO`S34C""/6%
M#&/#KBF%3?@P6ZR=#66<.D,RB)J[K#/!&!M0D=NR2;L*;-LX